Delivery of Immune Checkpoint Inhibitors Using Nanoparticles
Hala Gali-Muhtasib, Racha Chouaib in Nanoparticle Drug Delivery Systems for Cancer Treatment, 2020
Drug carriers can be defined as any substance that can enhance delivery, effectiveness, specificity, or safety of a drug. In the past few years, innovations in drug delivery systems have allowed easier routes of delivery of carrier-based DDSs. Also, now drug carriers of carrier-based DDSs are used to target drugs to specific tissues, in what is called targeted drug delivery [70–73]. Different drug carriers are currently used in carrier-based DDSs due to their benefits and few limitations (as detailed in the above section about Carrier-based delivery systems). A large variety of drug carriers exists and includes liposomes, niosomes, lipospheres, vesicles, dendrimers, polymeric micelles, liquid crystals, microspheres, hydrogels, implants, nanoparticles, among others. Below we describe some of these drug carriers and discuss nanoparticles in detail.
Improved Silymarin Characteristics for Clinical Applications by Novel Drug Delivery Systems
Madhu Gupta, Durgesh Nandini Chauhan, Vikas Sharma, Nagendra Singh Chauhan in Novel Drug Delivery Systems for Phytoconstituents, 2020
Novel drug delivery systems are mainly improved strategic drug carriers that facilitate controlling the pharmacokinetics, pharmacodynamics, and toxicity of therapeutic agents. These types of novel technologies can improve traditional medicine efficacy. Novel drug delivery system refers to the strategies to influence the fate of pharmaceutical compounds in the body with the aim of safely achieving its desired therapeutic properties. It combines polymer science, pharmaceutics, and molecular biology to achieve specific site-targeting, co‐delivering active constituents or facilitating systemic pharmacokinetics. It is usually concerned with both the quantity and the time of drug presence in the different parts of the human body (Bheemidi et al., 2011, Wang et al., 2015b).
Inhalation Drug Products Containing Nanomaterials
Anthony J. Hickey, Sandro R.P. da Rocha in Pharmaceutical Inhalation Aerosol Technology, 2019
There is a wide range of nanomaterials used in drug products (Doane and Burda 2012, Hubbell and Langer 2013, Kharisov et al. 2015, Peltonen and Hirvonen 2018, Quader and Kataoka 2017). One way to classify nanomaterials is regarding to their function in the drug product. According to a recent publication (D’Mello et al. 2017), the FDA’s Office of Pharmaceutical Quality at CDER classifies nanomaterials as: (i) APIs (e.g. nanocrystals, drug nanoparticles); (ii) drug carriers (e.g. drug encapsulated liposomes); (iii) excipients (e.g. drug-metal complexes), or (iv) complex/conjugates (e.g. drug-protein).
Synthesis of novel combinatorial drug delivery system (nCDDS) for co-delivery of 5-fluorouracil and leucovorin calcium for colon targeting and controlled drug release
Published in Drug Development and Industrial Pharmacy, 2021
Muhammad Usman Minhas, Orva Abdullah, Muhammad Sohail, Ikrima Khalid, Sarfaraz Ahmad, Kifayat Ullah Khan, Syed Faisal Badshah
Drug carrier system largely affected the efficacy of therapeutic agents during the transportation of drug to the specific part of body. Drug delivery carriers possibly minimize the various problems associated with conventional administration by drug targeting to specific site, prolonging time duration, control release rate, increased drug solubility, reducing side effect, and protecting from bioactivity [15–17]. Therefore, various drug delivery systems such as micelles [18], microsphere [19], nanoparticles [20], hydrogels and nanogels have been developed. Nanogels possess three dimensional physical and tunable chemical network structure and exhibit high water carrying capacity, good mechanical strength, and biocompatibility [21,22]. These nanogels have attained wide attraction in various fields like pharmaceutical, biomedical engineering, biomaterial science, and bio-nanotechnology [23–25].
Novel application of pluronic lecithin organogels (PLOs) for local delivery of synergistic combination of docetaxel and cisplatin to improve therapeutic efficacy against ovarian cancer
Published in Drug Delivery, 2018
Chia-En Chang, Chien-Ming Hsieh, Ling-Chun Chen, Chia-Yu Su, Der-Zen Liu, Hua-Jing Jhan, Hsiu-O Ho, Ming-Thau Sheu
Several drug carriers, including liposomes (Shaikh et al., 2013; Liu et al., 2014), dendrimers (Cai et al., 2015), silica nanoparticles (Chen et al., 2009), polymeric nanoparticles (Desale et al., 2013), and hydrogels (Cho et al., 2014; Desale et al., 2015; Ma et al., 2015; Wu et al., 2017) have been used to deliver two or more drugs (Hu et al., 2010). CPX-1, a liposome formulation containing irinotecan and floxuridine, is in a phase II trial for treating advanced colorectal cancer (Batist et al., 2008). CPX-351 (VYXEOS™) is another liposome formulation containing cytarabine and daunorubicin developed by Celator® Pharmaceuticals and is in a phase III clinical trial for refractory acute myeloid leukemia (Tardi et al., 2009; Feldman et al., 2011). Another example is Triolimus, a micelle formulation of three drugs (i.e. paclitaxel, rapamycin, and 17-AAG at a 2:1:3 molar ratio) which has been in a phase I clinical trial for angiosarcomas (Hasenstein et al., 2012).
Lowering side effects of NSAID usage in osteoarthritis: recent attempts at minimizing dosage
Published in Expert Opinion on Pharmacotherapy, 2018
Kevin H. Maniar, Ian A. Jones, Rayudu Gopalakrishna, C. Thomas Vangsness
Nano-formulations, encapsulation, and topical delivery were discussed as strategies to reduce NSAID dosage for treating osteoarthritis. Nano-formulations utilize nano-scale drug particles to increase dissolution and absorption. Nano-formulations have shown promise, and a few preparations are already commercially available and indicated for osteoarthritis. Encapsulation involves a drug carrier to facilitate a controlled drug release at the desired site of therapy. Many different carriers are currently being investigated including polymer-based carriers and lipid-based carriers. Topical delivery systems are locally applied, which limits their entrance into systemic circulation. Recognition of the benefits of topical preperations has led them to be increasingly included in osteoarthritis treatment guidelines. Development of new topical delivery systems is under investigation.
Related Knowledge Centers
- Diffusion
- Drug Delivery
- Micelle
- Pharmacokinetics
- Liposome
- Route of Administration
- Drug
- Bioavailability
- Microparticle
- Nanoparticle–Biomolecule Conjugate